Five U.S. companies joined a coalition of pharmaceutical companies that advocates for public policies and funding to support medical countermeasures to prevent and respond to a variety of threats.
Opiant, Roche Diagnostics, SCYNEXIS, Tonix, and Venatorx are the five newest members of this coalition, called the Alliance for Biosecurity. These companies represent a wide array of expertise that supports national health security.
“We welcome the newest members of the Alliance who have joined us to provide varying perspectives and contribute to our expanding scope. Together, we are uniquely equipped to help guide and further develop public-private partnerships that protect the American people from chemical, biological, radiological, or nuclear threats,” Alliance for Biosecurity Co-Chair Brent MacGregor said.
There are now 18 total companies and organizations in the coalition.
“The threats that would call our products into use are considered to have catastrophic potential,” Alliance Co-Chair Chris Frech said. “In the interest of preparedness and national security, industry and government work together to ensure that the necessary countermeasures are developed, manufactured, and delivered to the strategic national stockpile or that the infrastructure exists to respond to such emergencies. Because the U.S. government creates the demand for these products by authorizing funding for procurement and development, it benefits both sides to have clarity of requirements so industry can adequately meet the government’s needs.”
Opiant is a pharmaceutical company, Roche Diagnostics provides in vitro diagnostics solutions, SCYNEXIS is a biotech company, Tonix is a biopharmaceutical company, and Venatorx is a pharmaceutical company.
“For the Alliance to accurately represent industry in these situations, it is important that we have well-rounded knowledge to bring to these public-private partnerships. Our new members help give us a vast scope of expertise behind the same singular focus: strong and resilient national health security,” Frech added.